A carregar...

Adding Memantine to Rivastigmine Therapy in Patients With Mild-to-Moderate Alzheimer's Disease: Results of a 12-Week, Open-Label Pilot Study

Objective: At present, inhibition of cholines-terase is the treatment of choice for subjects with mild-to-moderate Alzheimer's disease (AD). Memantine, a noncompetitive antagonist at N-methyl-d-aspartate receptors, is currently used to treat subjects with moderate-to-severe AD. The goal of this...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Riepe, Matthias W., Adler, Georg, Ibach, Bernd, Weinkauf, Birgit, Gunay, Ibrahim, Tracik, Ferenc
Formato: Artigo
Idioma:Inglês
Publicado em: Physicians Postgraduate Press, Inc. 2006
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1764534/
https://ncbi.nlm.nih.gov/pubmed/17235381
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!